Childhood Arthritis and Rheumatology Research Alliance Biologic Disease‐Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis
- 14 August 2024
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (11) , 1532-1539
Abstract
Objective: The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease‐modifying antirheumatic drugs (bDMARDs).Methods: The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case‐based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM.Results: Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow‐up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab.Conclusion: CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry‐based prospective comparative effectiveness studies.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR041215)
This publication has 45 references indexed in Scilit:
- Parent Perspectives on Addressing Emotional Health for Children and Young Adults With Juvenile MyositisArthritis Care & Research, 2020
- Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis–Associated and Idiopathic Chronic Anterior UveitisArthritis Care & Research, 2019
- Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal LesionsArthritis Care & Research, 2018
- Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for New‐Onset Polyarticular Juvenile Idiopathic ArthritisArthritis Care & Research, 2013
- Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized sclerodermaArthritis Care & Research, 2012
- Consensus treatment plans for new‐onset systemic juvenile idiopathic arthritisArthritis Care & Research, 2012
- Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosusArthritis Care & Research, 2011
- Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus ConferenceArthritis Care & Research, 2011
- Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus ConferenceArthritis Care & Research, 2010
- Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patientsArthritis Care & Research, 2009